Hematologic Cancer Survivorship Management: Transplantation
This chapter will review the late effects of treatment impacting hematopoietic stem cell transplantation (HSCT) survivors. In general, HSCT patients receive high doses of chemotherapy with or without radiation therapy to eradicate their malignancy, together with an infusion of their own (autologous) or another person’s (allogeneic) stem cells to restore hematopoiesis (the blood and immune system). Allogeneic cells may be from bone marrow, peripheral blood, or umbilical cord blood obtained from a related or unrelated donor. Patients experience the toxic effects of the cytotoxic treatment and are at high risk for infections owing to posttransplant immune deficiency. Late effects for HSCT survivors are commonly compounded by the toxic effects of their previous cancer treatment. This chapter will cover physiologic and psychological aspects of survivorship for HSCT patients, as well as graft-versus-host disease, a common and frequently chronic condition that occurs after allogeneic HSCT.
KeywordsHematopoietic Stem Cell Transplantation Total Body Irradiation Acute GVHD Allogeneic Hematopoietic Stem Cell Transplantation Chronic GVHD
- Flomenberg N, Baxter-Lowe LA, Confer D, et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood 2004;104:1923–1930.PubMedCrossRefGoogle Scholar
- Lee SJ, Flowers ME. Recognizing and managing chronic graft-versus-host disease. Hematology Am Soc Hematol Educ Program 2008:134–141.Google Scholar
- Loren AW, Chow E, Jacobsohn DA, et al. Pregnancy after hematopoietic cell transplantation: a report from the late effects working committee of the Center for International Blood and Marrow Transplant Research (CIBMTR). Biol Blood Marrow Transplant 2011;17:157–166.PubMedCrossRefPubMedCentralGoogle Scholar
- Robin M, Porcher R, De Castro Araujo R, et al. Risk factors for late infections after allogeneic hematopoietic stem cell transplantation from a matched related donor. Biol Blood Marrow Transplant 2007;13:1304–1312.Google Scholar